Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Jeffrey Montgomery to Aged, 80 and over

This is a "connection" page, showing publications Jeffrey Montgomery has written about Aged, 80 and over.

 
Connection Strength
  
 
 
0.611
  
  1. Lee MS, Shen M, Williams A, Kendrick D, Weizer A, Montgomery J. Retroureteral Small Bowel Herniation Resulting in Bowel Obstruction Following Robotic Cystectomy With Extracorporeal Ileal Conduit. Urology. 2021 01; 147:3-6.
    View in: PubMed
    Score: 0.107
  2. Montgomery JS, Weizer AZ, Montie JE. Editorial comment. Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology. 2011 Mar; 77(3):667-8.
    View in: PubMed
    Score: 0.056
  3. D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Soria F, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World J Urol. 2021 Dec; 39(12):4345-4354.
    View in: PubMed
    Score: 0.029
  4. Abdulfatah E, Reichert ZR, Davenport MS, Chinnaiyan AM, Dadhania V, Wang X, Mannan R, Kunju LP, Hollenbeck BK, Montgomery JS, Kaffenberger SD, Morgan TM, Alva AS, Palapattu GS, Vaishampayan UN, Alumkal JJ, Spratt DE, Udager AM, Mehra R. De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome. Med Oncol. 2021 Feb 14; 38(3):26.
    View in: PubMed
    Score: 0.028
  5. Sessine MS, Weizer A, Kirk PS, Borza T, Jacobs BL, Qin Y, Oerline M, Li B, Modi PK, Lavieri MS, Gilbert SM, Montgomery JS, Hollenbeck BK, Urish K, Helm JE, Skolarus TA. Reframing Financial Incentives Around Reducing Readmission After Radical Cystectomy. Urology. 2020 08; 142:99-105.
    View in: PubMed
    Score: 0.026
  6. Simon CT, Skala SL, Magers MJ, Weizer A, Kaffenberger SD, Chinnaiyan AM, Spratt DE, Montgomery J, Mehra R, Lew M. The utility of upper urinary tract urine cytology before and after application of the Paris system. Diagn Cytopathol. 2019 May; 47(5):421-427.
    View in: PubMed
    Score: 0.024
  7. Simon CT, Skala SL, Weizer AZ, Ambani SN, Chinnaiyan AM, Palapattu G, Hafez K, Magers MJ, Kaffenberger SD, Spratt DE, Montgomery JS, Morgan TM, Udager AM, Lew M, Mehra R. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma. Hum Pathol. 2019 04; 86:76-84.
    View in: PubMed
    Score: 0.024
  8. Modi PK, Hollenbeck BK, Oerline M, Weizer AZ, Montgomery JS, Kaffenberger SD, Ryan AM, Ellimoottil C. Real-World Impact of Minimally Invasive Versus Open Radical Cystectomy on Perioperative Outcomes and Spending. Urology. 2019 03; 125:86-91.
    View in: PubMed
    Score: 0.024
  9. Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Venkatramani V, Soodana-Prakash N, Kendrick K, Smith JA, Thompson IM. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018 06 23; 391(10139):2525-2536.
    View in: PubMed
    Score: 0.023
  10. Brown NA, Lew M, Weigelin HC, Weizer AZ, Montgomery JS, Betz BL, Mehra R. Comparative study of TERT promoter mutation status within spatially, temporally and morphologically distinct components of urothelial carcinoma. Histopathology. 2018 01; 72(2):354-356.
    View in: PubMed
    Score: 0.022
  11. Osawa T, Ambani SN, Olugbade K, Skolarus TA, Weizer AZ, Montgomery JS, He C, Hafez KS, Hollenbeck BK, Lee CT, Montie JE, Palapattu GS, Morgan TM. Potential Implications of Shortening Length of Stay Following Radical Cystectomy in a Pre-ERAS Population. Urology. 2017 04; 102:92-99.
    View in: PubMed
    Score: 0.021
  12. Osawa T, Hafez KS, Miller DC, Montgomery JS, Morgan TM, Palapattu GS, Weizer AZ, Caoili EM, Ellis JH, Kunju LP, Wolf JS. Comparison of Percutaneous Renal Mass Biopsy and R.E.N.A.L. Nephrometry Score Nomograms for Determining Benign Vs Malignant Disease and Low-risk Vs High-risk Renal Tumors. Urology. 2016 Oct; 96:87-92.
    View in: PubMed
    Score: 0.020
  13. Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess RT, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM. Independent surgical validation of the new prostate cancer grade-grouping system. BJU Int. 2016 Nov; 118(5):763-769.
    View in: PubMed
    Score: 0.020
  14. McDaniel AS, Hovelson DH, Cani AK, Liu CJ, Zhai Y, Zhang Y, Weizer AZ, Mehra R, Feng FY, Alva AS, Morgan TM, Montgomery JS, Siddiqui J, Sadis S, Bandla S, Williams PD, Cho KR, Rhodes DR, Tomlins SA. Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. Cancer Res. 2015 Dec 15; 75(24):5219-27.
    View in: PubMed
    Score: 0.019
  15. Osawa T, Hafez KS, Miller DC, Montgomery JS, Morgan TM, Palapattu GS, Weizer AZ, Caoili EM, Ellis JH, Kunju LP, Wolf JS. Age, Gender and R.E.N.A.L. Nephrometry Score do not Improve the Accuracy of a Risk Stratification Algorithm Based on Biopsy and Mass Size for Assigning Surveillance versus Treatment of Renal Tumors. J Urol. 2016 Mar; 195(3):574-80.
    View in: PubMed
    Score: 0.019
  16. Udager AM, Pan J, Magers MJ, Palapattu GS, Morgan TM, Montgomery JS, Weizer AZ, Hafez KS, Miller DC, Wolf JS, McHugh JB, Chinnaiyan AM, Dhanasekaran SM, Mehra R. Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma. Am J Surg Pathol. 2015 Apr; 39(4):549-57.
    View in: PubMed
    Score: 0.019
  17. McDaniel AS, Zhai Y, Cho KR, Dhanasekaran SM, Montgomery JS, Palapattu G, Siddiqui J, Morgan T, Alva A, Weizer A, Lee CT, Chinnaiyan AM, Quist MJ, Grasso CS, Tomlins SA, Mehra R. HRAS mutations are frequent in inverted urothelial neoplasms. Hum Pathol. 2014 Sep; 45(9):1957-65.
    View in: PubMed
    Score: 0.018
  18. Hu M, Jacobs BL, Montgomery JS, He C, Ye J, Zhang Y, Brathwaite J, Morgan TM, Hafez KS, Weizer AZ, Gilbert SM, Lee CT, Lavieri MS, Helm JE, Hollenbeck BK, Skolarus TA. Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer. Cancer. 2014 May 01; 120(9):1409-16.
    View in: PubMed
    Score: 0.017
  19. Schroeck FR, Kaufman SR, Jacobs BL, Zhang Y, Weizer AZ, Montgomery JS, Gilbert SM, Strope SA, Hollenbeck BK. The impact of technology diffusion on treatment for prostate cancer. Med Care. 2013 Dec; 51(12):1076-84.
    View in: PubMed
    Score: 0.017
  20. Filson CP, Montgomery JS, Dailey SM, Crossley HS, Lentz H, Tallman CT, He C, Weizer AZ. Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection. Urol Oncol. 2014 Jan; 32(1):40.e1-8.
    View in: PubMed
    Score: 0.016
  21. Grivas PD, Hussain M, Hafez K, Daignault-Newton S, Wood D, Lee CT, Weizer A, Montie JE, Hollenbeck B, Montgomery JS, Alva A, Smith DC. A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. Urology. 2013 Jul; 82(1):111-7.
    View in: PubMed
    Score: 0.016
  22. Halverson SJ, Kunju LP, Bhalla R, Gadzinski AJ, Alderman M, Miller DC, Montgomery JS, Weizer AZ, Wu A, Hafez KS, Wolf JS. Accuracy of determining small renal mass management with risk stratified biopsies: confirmation by final pathology. J Urol. 2013 Feb; 189(2):441-6.
    View in: PubMed
    Score: 0.016
  23. Shah RB, Montgomery JS, Montie JE, Kunju LP. Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol. 2013 Nov; 31(8):1650-5.
    View in: PubMed
    Score: 0.015
  24. Skolarus TA, Ye Z, Montgomery JS, Weizer AZ, Hafez KS, Lee CT, Miller DC, Wood DP, Montie JE, Hollenbeck BK. Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries. Urology. 2011 Dec; 78(6):1345-9.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.